Medesis Pharma
  • en
  • fr
  • Corporate
    • General presentation
    • Historical
    • Governance
    • Supervisory board
    • Scientific Advisory board
  • Technology
    • Description
    • Advantages
    • Historical
  • Pipeline
  • Clinical
    • Alzheimer’s disease
  • Pre-clinical
    • Neurology
    • Cancer
    • Nuclear
  • Investors
    • Share information
    • Press release
    • Reports and documents
    • Regulated information
    • General Meetings
    • Agenda & Contact
  • Scientific publications
  • Contacts
Select Page
We develop new drugs to preserve life

We develop new drugs to preserve life

by Thibaut | Jun 13, 2021 | Banner in one

Medesis is a clinical development stage biopharmaceutical company that is engaged in the development of orally administered molecule drug candidates to address major unmet medical needs.
Covid-19 treatments using drug delivery technology

Covid-19 treatments using drug delivery technology

by Gilles Petitot | Mar 30, 2020 | Banner in one

Breakthrough technology to optimize drug administration

Breakthrough technology to optimize drug administration

by Thibaut | Jun 13, 2017 | Banner in one

AONYS® allows the administration of low doses of water-soluble pharmaceutical active ingredients. The final product is deposited on the mucosa of the mouth and delivered directly into the cells of the whole body
Preserving the brain in neurodegenerative diseases

Preserving the brain in neurodegenerative diseases

by Thibaut | Jun 13, 2017 | Banner in one

NP03 is a disease-modifying nano dose formulation of lithium citrate in an AONYS® reverse microemulsion. NP03 allows the delivery of lithium citrate to all tissues with a strong therapeutic efficacy at low doses.
Improve the lives of patients suffering from Alzheimer

Improve the lives of patients suffering from Alzheimer

by Thibaut | Jun 13, 2017 | Banner in one

Preclinical studies on the disease-modifying effect of NP03 in AD have been conducted in McGill University, Montreal CA. NP03 is a disease modifying drug and induced neurogenesis. A phase II is planned for the treatment of psychosis associated with AD.
Drugs for populations contaminated during a nuclear accident

Drugs for populations contaminated during a nuclear accident

by Thibaut | Jun 13, 2017 | Banner in one

After a civil or military nuclear accident, there are no suitable decorporation treatments for large contaminated populations and no approved drug to be used after irradiation and free of serious side effects.
« Older Entries

Recent Posts

  • Alzheimer’s disease
  • We develop new drugs to preserve life
  • Investors
  • Medesis Pharma & Transgene prolongent leur accord de recherche collaborative
  • NanoSIRNA

Recent Comments

    Archives

    • August 2021
    • June 2021
    • January 2021
    • November 2020
    • March 2020
    • July 2019
    • October 2017
    • September 2017
    • July 2017
    • June 2017

    Categories

    • Banner in one
    • Clinical stage products
    • In one
    • Investors
    • Non classé
    • Preclinical stage product
    • Press news
    • Research
    • Technology

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • Facebook
    • Twitter
    • Instagram
    • RSS

    Designed by Elegant Themes | Powered by WordPress

    Manage Cookie Consent
    We use cookies to optimize our website and our service. Cookie Policy
    Functional Always active
    The storage or technical access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication on an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Marketing
    The technical storage or access that is used exclusively for statistical purposes. Technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance by your ISP, or additional third-party records, information stored or retrieved for this purpose alone generally cannot be used to identify you.
    Marketing
    Storage or technical access is required to create user profiles to send advertising, or to track the user across one or multiple websites for similar marketing purposes.
    Manage options Manage services Manage vendors Read more about these purposes
    Personalize
    {title} {title} {title}